Neuphoria Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Neuphoria Therapeutics Inc. (NASDAQ: NEUP, formerly known as Bionomics Limited) is a clinical-stage biotechnology company dedicated to developing novel allosteric ion channel modulators for the treatment of central nervous system (CNS) and neuropsychiatric disorders. The company's lead drug candidate is BNC210, an oral, proprietary, selective negative allosteric modulator of the alpha-7 (́7) nicotinic acetylcholine receptor. Neuphoria also maintains a strategic partnership with Merck & Co. to develop ́7 receptor positive allosteric modulators (PAMs) targeting cognitive dysfunction associated with Alzheimer's disease and other CNS conditions. The company completed its corporate re-domiciliation from Australia to Delaware, USA, in December 2024, transitioning its primary listing to the Nasdaq Global Market.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Evaluation of potential strategic alternatives, including mergers, acquisitions, partnerships, or licensing transactions, to maximize stockholder value.
Expected impact: Aims to secure a strategic transaction or corporate sale to preserve and realize the value of the company's pipeline and partnerships.
Implementation of aggressive cash conservation measures following the clinical failure of BNC210 in social anxiety disorder, including pausing internal R&D programs, terminating facility leases, and laying off the majority of staff.
Expected impact: Significantly reduces cash burn and extends the company's remaining cash runway to support the strategic review process.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Exclusive worldwide license agreement for the development of alpha-7 nicotinic acetylcholine receptor positive allosteric modulators, including MK-1167.
Terms: Neuphoria received a $15 million milestone payment in February 2025 upon the initiation of a Phase 2 trial for MK-1167. The company is eligible to receive up to $450 million in additional development and commercial milestones, plus royalties on net sales.
Exclusive license of the legacy oncology program BNC101 (a monoclonal antibody targeting LGR5) for the development of CAR-T therapies.
Terms: Neuphoria is eligible to receive up to AUD 118 million in milestone payments plus royalties on net sales.